Arylsulfonamide derivatives

1. A compound of formula I and pharmaceutically acceptable salts thereof:

wherein

A is O, CO, S, NR d , or CR b R c ;

D is COR 4 , C(O)NR d R 4 , C(O)OR 4 ;

X, Y and Z are independently a ring carbon atom or a ring nitrogen atom, with the proviso that 0-3 X, 0-3 Y and 0-3 Z are ring nitrogen atoms;

R 1a and R 1b are independently selected from (1) H, (2) halogen, (3) C 1-6 alkyl optionally substituted with 1-5 groups independently selected from halogen, nitro, cyano, COR a , CO 2 R a , C(O)NR d R e , OR a , OC(O)R a , SR a , SO 2 R f , S(O)R f , NR d R e , NR d C(O)R a and NR d SO 2 R f , (4) C(O)R a , (5) CO 2 R a , (6) C(O)NR d R e , (7) OR a , (8) OC(O)R a , (9) OC(O)NR d R e , (10) NR d R e , (11) NR d C(O)R a , (12) NR d C(O)OR a , (13) NR d C(O)NR d R e , (14) NR d SO 2 R f , (15) SR a , (16) S(O)R f , (17) SO 2 R f , (18) SO 2 NR d R e , (19) CN, (20) NO 2 , (21) optionally substituted aryl, (22) optionally substituted heteroaryl, (23) optionally substituted heterocyclyl, (24) optionally substituted aryl-C 1-6 alkyl, (25) optionally substituted heteroaryl-C 1-6 alkyl, and (26) optionally substituted heterocyclyl-C 1-6 alkyl; wherein the substituents for aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR a , NR d R e , NR d C(O)R a , NR d SO 2 R f , OC(O)R a , NR d C(O) 2 R a , SR a , SO 2 R f , oxo (for heterocyclyl and heterocyclylalkyl), C(O)R a , C(O) 2 R a , C 1-4 alkyloxy, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, C 3-6 cycloalkyl and C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms, or

R 1a , R 1b and adjacent carbon atoms to which they are attached together form a saturated, partially unsaturated or aromatic 5- or 6-membered ring containing 0 to 2 heteroatoms selected from N, N—R g , O and S;

R 2a and R 3a are independently selected from (1) H, (2) halogen, (3) OR a , (4) NR d R e , (5) CN, (6) NO 2 , (7) CO 2 R a , (8) COR a , and (9) C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms,

R 4 is selected from (1) C 1-6 alkyl substituted with 1 to 5 halogen atoms, OR a , NR d R e or C(O)NR d R e in which, for these two occurrences, R d and R e together complete a 4- to 8-membered ring optionally containing an additional heteroatom selected from NR g , O, S, and SO 2 , and said ring being optionally fused to a benzene or a 5- or 6-membered heteraromatic ring, and optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, nitro, OR g , oxo. C 3-6 cycloalkyl, aryl, heteroaryl, NR g R g , NR g COR g , NR g CO 2 R g and C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms; (2) optionally substituted heteroaryl; (3) optionally substituted heteroaryl-C 1-4 alkyl; (4) optionally substituted heterocyclyl; (5) optionally substituted heterocyclyl-C 1-4 alkyl; wherein the substituents for heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR a , NR d R e , NR d C(O)R a , NR d SO 2 R f , OC(O)R a , NR d C(O) 2 R a , SR a , SO 2 R f , oxo (for heterocyclyl and heterocyclylalkyl), C(O)R a , C(O) 2 R a , C 1 -4alkyloxy, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, C 3-6 cycloalkyl and C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms;

R a is (1) H, (2) C 1-6 alkyl optionally substituted with 1 to 5 groups independently selected from halogen, cyano, nitro, OH, C 1-4 alkyloxy and C 3-6 cycloalkyl, (3) C 3-6 cycloalkyl, (4) optionally substituted aryl, (5) optionally substituted heteroaryl, (6) optionally substituted heterocyclyl, (7) optionally substituted aryl-C 1-6 alkyl, (8) optionally substituted heteroaryl-C 1-6 alkyl, and (9) optionally substituted heterocyclyl-C 1-6 alkyl; wherein the substituents for aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR g , NR d R e , NR d C(O)R g , NR d SO 2 R f , OC(O)R g , NR d C(O) 2 R g , SR g , SO 2 R f , oxo (for heterocyclyl and heterocyclylalkyl), C(O)Rg a , C(O) 2 R g , C 1-4 alkyloxy, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, C 3-6 cycloalkyl and C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms;

R b and R c are independently selected from H, halogen, or C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms;

R d and R e are independently selected from (1) H, (2) C 1-4 alkyl, optionally substituted with 1 to 5 groups independently selected from halogen, amino, mono-C 1-4 alkylamino, di-C 1-4 alkylamino, and SO 2 R f , (3) aryl-C 1-6 alkyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OH, C 1-4 alkyloxy, C 3-6 cycloalkyl and C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms, (4) heteroaryl-C 1-6 alkyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OH, C 1-4 alkyloxy, C 3-6 cycloalkyl and C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms,and (5) C 3-6 cycloalkyl, or

R d and R e , or R d and R 4 , together with the atom or atoms to which they are attached, complete a 4- to 8-membered saturated, partially saturated or aromatic ring optionally containing 1 to 3 heteroatoms independently selected from N, NR g , O, S, and SO 2 , and said ring being optionally fused to a benzene or a 5- or 6-membered heteraromatic ring, and optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, nitro, OR g , oxo, C 3-6 cycloalkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, NR g R g , NR g COR g , NR g CO 2 R g and C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms;

R f is selected from (1) C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms, (2) C 1-4 alkyloxy, and (3) aryl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OH, C 1-4 alkyloxy, C 3-6 cycloalkyl and C 1-4 alkyl optionally substituted with 1 to 5 halogen atoms;

R g is selected from (1) H, (2) C 1-4 alkyl, (3) aryl, (4) aryl-C 1-6 alkyl, (5) C(O) 2 C 1-4 alkyl and (6) C(O)C 1-4 alkyl.

2. A compound of claim 1 wherein A is C(O) or O.

3. A compound of claim 1 wherein each occurrence of Y and Z represents a ring carbon atom, and one X is a ring carbon or nitrogen atom and the others are ring carbon atoms.

4. A compound of claim 1 having the formula Ia(1) and pharmaceutically acceptable salts thereof:

wherein

A is O or C(O);

one of X is a ring carbon or nitrogen atom, and the others are ring carbon atoms;

R 1a and R 1b are independently selected from hydrogen, halogen, C 1-4 alkyl, cyano, SR a , OR a and CF 3 ;

R 2a and R 3a are independently H or halogen;

R 4 is selected from (1) C 1-4 alkyl substituted with one to 5 groups independently selected from halogen, C 3-6 cycloalkyl, NR d R e , NR d C(O) 2 R a , C(O)NR d R e , C(O)OR a , and OR a ; (2) C 3-6 cycloalkyl; (3) phenyl: (4) phenyl-C 1-4 alkyl; (5) optionally substituted heteroaryl; (6) optionally substituted heteroaryl-C 1-4 alkyl; (7) optionally substituted heterocyclyl; and (8) optionally substituted heterocyclyl-C 1-4 alkyl; wherein heteroaryl, including as part of heteroarylalkyl, is selected from benzofuranyl, pyrazolo[1.5-a]pyrimidinyl, 1-azaindolizinyl, s-triazolo[1,5-a]pyrimidinyl, thieno[3,2-b]pyridinyl, isoxazolyl, pyrazinyl, pyrazolyl, pyrimidinyl, benzisoxazolyl, pyridyl, indolyl, benzimidazolyl, benzthiazolyl and imidazo[2,1-b]thiazolyl; heterocyclyl, including as part of heterocyclylalkyl, is selected from morpholinyl, tetrahydropyranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl and imidazolidinyl; the substituents for heteroaryl is 1 or 2 groups independently selected from C 1-4 alkyl, C 3-6 cycloalkyl, and OR a ; and the substituents for heterocyclyl is 1 to 3 groups independently selected from oxo and C 1-4 alkyl,

R a and R d are as defined in claim 1 .

5. A compound of claim 4 wherein R 4 is selected from (1) C 1-4 alkyl substituted with NR d R e or C(O)NR d R e where for both groups R d and R e , together with the nitrogen atom to which they are attached, complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NR g , O, S and SO 2 , and wherein said substituent is 1 or 2 groups independently selected from OR a , halogen, C 1-4 alkyl and oxo; (2) optionally substituted heteroaryl wherein said heteroaryl is selected from pyrazolyl, isoxazolyl, pyrimidinyl, benzofuranyl, pyrazolo[1,5-a]pyrimidinyl, 1-azaindolizinyl, s-triazolo[1,5-a]pyrimidinyl, imidazo[2,1-b]thiazolyl, thieno[3,2-b]pyridinyl, and said substituent is 1 to 3 groups independently selected from furanyl, pyridyl, benzyl, phenyl optionally substituted with halogen, C 1-4 alkyl, C 3-6 cycloalkyl, trifluoromethyl, halogen, and C 1-4 alkoxy.

6. A compound of claim 1 having a formula Ia(2) and pharmaceutically salts thereof:

wherein R d is H and R 4 is selected from (1) C 1-4 alkyl substituted with a group selected from halogen, OR a , CO 2 R a , NHCOR a , NR d R e and C(O)NR d R e ; (2) optionally substituted heteroaryl-C 1-4 alkyl wherein heteroaryl is selected from azaindolizinyl, imidazolyl, benzimidazolyl, pyrazinyl, pyridyl, indolyl, triazolyl, thiazolyl, imidazo[1,2-a]pyridyl, imidazo[1,2-a]pyrimidinyl, imidazo[2,1-b]thiazolyl, and pyrazolo[1,5-a]-pyrimidinyl; (3) optionally substituted heterocycylyl-C 1-4 alkyl wherein heterocyclyl is selected from tetrahydropyranyl, tetrahydrofuranyl and dioxanyl; (4) optionally substituted heterocyclyl selected from pyrrolidinyl and piperidinyl; (5) CO 2 R a ; (6) C 3-6 cycloalkyl; and (7) optionally substituted phenyl-C 1-4 alkyl; or R d and R 4 together with the nitrogen atom to which they are attached complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NR g , O, S and SO 2 , wherein said ring is optionally fused to a benzene or a 5- or 6-membered heteroaryl ring, and said substituent is 1 or 2 groups independently selected from OR a , halogen, C 1-4 alkyl, NR d R e , NR d CO2R a , and oxo.

7. A compound of claim 6 wherein R d is H and R 4 is selected from (1) C 1-4 alkyl substituted with NR d R e or C(O)NR d R e , wherein for both groups R d and R e together with the nitrogen to which they are attached complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NR g , O, S and SO 2 , and wherein said substituent is 1 or 2 groups independently selected from OR a , halogen, C 1-4 alkyl and oxo; (2) heterocyclyl or heterocyclyl-C 1-4 alkyl wherein said heterocyclyl is selected from pyrrolidinyl, 1,4-dioxanyl, and tetrahydropyranyl; and (3) heteroaryl-C 1-4 alkyl optionally substituted with 1 to 3 C 1-4 -alkyl groups, wherein said heteroaryl is selected from imidazolyl, 1-azaindolizinyl, imidazo[2,1-b]thiazolyl, and pyrimidinyl.

8. A compound of claim 1 having the formula Ia(3) an pharmaceutically acceptable salts thereof:

wherein R 4 is selected from (1) C 2-4 alkyl substituted with NR d R e or C(O)NR d R e in which, for these two groups, R d and R e together with the nitrogen atom to which they are attached complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NR g , O, S and SO 2 , and wherein said substituent is 1 or 2 groups independently selected from OR a , halogen, C 1-4 alkyl and oxo; (2) heterocyclyl-C 1-4 alkyl optionally substituted with 1 to 3 groups independently selected from C 1-4 alkyl and oxo, wherein heterocyclyl is selected from tetrahydropyranyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, oxazolidinyl, dioxanyl, and dioxolanyl; (3) furanyl-C 1-4 alkyl; and (4) phenyl-C 1-4 alkyl.

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.

10. A method for the treatment of diseases or disorders mediated through the bradykinin receptor pathway which comprises administering to a patient in need thereof a compound of formula I or a pharmaceutically acceptable salt thereof.

11. The method of claim 10 wherein said disease or disorder is selected from neuropathic pain, acute pain and inflammatory pain.